ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2014

Abstract Number: 2770

Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?

Stavros Chrysidis1, Philip Rask Lage-Hansen1 and Andreas P. Diamantopoulos2, 1Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, 2Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: giant cell arteritis, large vessel vasculitis, Polymyalgia rheumatica and ultrasound

Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Large Vessel Vasculitis (LVV) can present with heterogeneous clinical manifestations, which range from general symptoms (fever, loss of weight) to the classic symptoms of  Giant Cells Arteritis (GCA)  (headache, jaw claudication, visual manifestations). Around 40% of GCA  patients have concomitant Polymyalgia Rheumatica (PMR) and up to 40% of PMR  patients have a positive biopsy of the temporal artery (TAB).

Studies evaluating ultrasound (US) as a diagnostic tool in GCA have reported a high sensivity and specificity.

The aim of this study was to investigate the association between disease’s relapse and co-existing “silence” LVV in patients with pure PMR.

Methods

Patients with PMR who relapsed under corticosteroid (CS) tapering In Esbjerg Hospital, Denmark in the period of April 2013 to June 2014 have been prospectively included. In patients with PMR who relapsed under corticosteroid (CS) tapering,  US examination of temporal (AT), axillary (AA), subclavian (AS) and carotid (AC) arteries was performed. US images were recorded and evaluated by an ultrasonographer experienced on vascular ultrasound (AD), who was blinded to patients’ clinical and laboratory data.

US was considered positive when a homogeneous hypoechoic thickness >1.5 mm in AC and AS and >1mm in AA, in transverse and longitudinal view was observed.  For the AT, the typical sign of halo (arterial wall swelling in transverse and longitudinal view) was considered as vasculitis. Relapse was defined as the reappearance of PMR clinical symptoms in addition to elevated ESR or CRP (ESR> 40 mm/h, CRP>10mg/lt) or persistent increased CRP/SR without any other explanation. All patients with positive US findings underwent a TAB.

Results

On a period of 14 months, 17 patients had been evaluated. All patients fulfilled the Bird’s classifications criteria for PMR and all the patients responded appropriately to CS treatment at baseline. None of the patients had GCA- related clinical symptoms either on baseline or during the relapse. No significant differences were observed between the two groups of patients (PMR + LVV and PMR – LVV) in age, diseases duration, initial CRP/SR levels and initial CS dose (prednisolon 15-25mg).

Seven out of 17 (41%) patients had ultrasonographic sign of vasculitis. All patients had affection of the AA (6 of them bilateral), 3 of the AS, 1 of the AT none of the AC. The patient with the positive US of the AT was the only who had a positive TAB.

Conclusion

In our study, the relationship between PMR relapse and concomitant “silence” LVV has been evaluated. More than one-third of PMR patients who relapsed had a co-existing LVV.  Thus, we recommend the use of vascular US in all patients with PMR suffering a relapse to investigate the possible co-existence of LVV.


Disclosure:

S. Chrysidis,
None;

P. R. Lage-Hansen,
None;

A. P. Diamantopoulos,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/polymyalgia-rheumatica-relapse-and-silence-large-vessel-vasculitis-is-there-any-association/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology